Endometrioid adenocarcinoma
MONDO:0005026An adenocarcinoma characterized by the presence of malignant glandular epithelial cells resembling endometrial cells. It can arise from the uterine body, ovary, fallopian tube, cervix, vagina, and uterine ligament.
Also known as: endometrioid adenocarcinoma, endometrioid carcinoma, endometrioid carcinoma of female reproductive system, endometrioid carcinoma of the female reproductive system, female reproductive endometrioid carcinoma
2975 clinical trials for this condition and its sub-types, 12 tagged with Endometrioid adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Endometrioid adenocarcinoma
-
Ovarian endometrioid adenocarcinoma 77 trials
1 sub-type
-
Endometrial endometrioid adenocarcinoma 55 trials
5 sub-types
- Endometrial endometrioid adenocarcinoma with spindled epithelial cells 0 trials
- Mucin-rich endometrial endometrioid adenocarcinoma 0 trials
- Oxyphilic endometrial endometrioid adenocarcinoma 0 trials
- Secretory uterine corpus endometrioid adenocarcinoma 0 trials
- Villoglandular endometrial endometrioid adenocarcinoma 0 trials
-
Stage I endometrioid carcinoma 16 trials
-
Stage II endometrioid carcinoma 2 trials
-
Cervical endometrioid adenocarcinoma 0 trials
1 sub-type
-
New drug cocktails show promise against tough endometrial cancer
Disease control OngoingThis study tests several drug combinations in women with endometrial cancer that has returned or not responded to treatment. The drugs work by blocking cancer cell growth or helping the immune system attack tumors. The goal is to see if these combinations can slow or stop the can…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…
Phase 1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC